Earnings Feed
Start Free
$MXCT·8-K

MAXCYTE, INC. · Mar 27, 4:54 PM ET

Compare

MAXCYTE, INC. 8-K

Research Summary

AI-generated summary

Updated

MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer

What Happened
MaxCyte, Inc. filed an 8-K on March 27, 2026, announcing that the Board appointed Parmeet Ahuja as Chief Financial Officer and principal accounting officer, effective March 30, 2026. Mr. Ahuja, 57, succeeds Douglas Swirsky (previously announced to be transitioning). He joins from Agilent Technologies, where he served as Vice President, Investor Relations (Aug 2021–Oct 2025) and earlier as VP, Financial Planning & Analysis, Operations and Supply Chain (Jul 2017–Jul 2021). Mr. Ahuja holds an MBA from San Jose State University and a B.Com (Hons) from Delhi University.

Key Details

  • Appointment effective date: March 30, 2026; 8-K filed March 27, 2026.
  • Cash compensation: annual base salary $450,000 and eligible for an annual cash performance bonus with a 50% target.
  • Equity awards: nonqualified stock option to purchase 375,000 shares and a restricted stock unit award for 187,500 shares (granted as an inducement).
  • Severance framework: if terminated without “cause” or resigns for “good reason” near a change in control (within 3 months prior or during the 12-month post-change window) Mr. Ahuja would receive 12 months’ base pay, 100% of target bonus paid over 12 months, up to 12 months COBRA, and full acceleration of unvested equity; if termination occurs more than 3 months before a change in control, he would receive 9 months’ base pay and up to 9 months COBRA (with certain offsets).

Why It Matters
A new CFO can affect financial reporting, investor communications, and strategic financial decisions. Mr. Ahuja brings over 20 years of finance leadership at a large, publicly traded life‑sciences company, which may reassure investors about continuity in financial oversight. The compensation package—notably significant equity grants and severance protections tied to change‑of‑control events—aligns his incentives with stock performance but could have dilution or cash/benefit implications if severance triggers occur. The filing notes no related‑party transactions or special arrangements in his selection.

Loading document...